Profound Medical (PROF) Cash & Equivalents (2018 - 2026)

Profound Medical's Cash & Equivalents history runs 9 years deep, the most recent figure standing at $50.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 8.32% year-over-year to $50.3 million; the TTM figure through Mar 2026 stood at $50.3 million (up 8.32% YoY), while the FY2025 annual figure was $59.7 million, up 8.76% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $50.3 million, down from $59.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $59.7 million in Q4 2025, with the low at $24.8 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $46.5 million (2022), against an average of $43.0 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 43.65% in 2023, then jumped 109.48% in 2024.
• Profound Medical's Cash & Equivalents stood at $46.5 million in 2022, then tumbled by 43.65% to $26.2 million in 2023, then soared by 109.48% to $54.9 million in 2024, then advanced by 8.76% to $59.7 million in 2025, then dropped by 15.79% to $50.3 million in 2026.
• Business Quant data shows PROF's Cash & Equivalents at $50.3 million in Q1 2026, $59.7 million in Q4 2025, and $24.8 million in Q3 2025.